Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Bo Geum Kong"'
Autor:
Young-Soo Seo, Dong-Wook Jeon, Bo-Geum Kong, Jung-Joon Moon, Do-Un Jung, Joo-Cheol Shim, Sung-Jin Kim, Minkyung Oh
Publikováno v:
Schizophrenia Research. 176:206-211
Objectives Smoking is more common among patients with schizophrenia than it is in the general population. Varenicline, a partial and full agonist at the α4β2 and α7 nicotine acetylcholine receptors, respectively, has been shown to be an effective
Autor:
Sae Heon Jang, Woo Young Jung, Young Myo Jae, Ho Chan Kim, Byeong Moo Choe, Jeong Gee Kim, Sung Gon Kim, Bo Geum Kong, Choongrak Kim
Publikováno v:
Psychiatry Investigation
ObjectiveaaThe aim of the present study was to investigate differences in discontinuation time among antidepressants and total antide pressant discontinuation rate of patients with depression over a 6 month period in a naturalistic treatment setting.
Autor:
Sung-Jin Kim, Do-Un Jung, Jung-Joon Moon, Je-Wook Kang, Dong-Wook Jeon, Beom-Joo Seo, Bo-Geum Kong, Sung-Soo Jung, Joo-Cheol Shim
Publikováno v:
Clinical Psychopharmacology and Neuroscience
Objective Cognitive dysfunction is common in people with schizophrenia, and language disability is one of the most notable cognitive deficits. This study assessed the use and comprehension ability of the Korean language in patients with schizophrenia
Autor:
Yoon-Ho Lee, Eun-Chan Kang, Dong-Wook Jeon, Hyun-Bin Ju, Jung Min Kim, Bo-Geum Kong, Do-Un Jung, Je-Wook Kang, Jung-Joon Moon
Publikováno v:
Journal of the Korean Academy of Child and Adolescent Psychiatry. 26:279-287
Autor:
Bo-Geum Kong, Seung-Ju Lee, Minkyung Oh, Je-Wook Kang, Do-Un Jung, Joo-Cheol Shim, Deanna L. Kelly
Publikováno v:
Journal of Clinical Psychopharmacology. 31:406-410
Objective People with schizophrenia are at a higher risk for osteoporosis. The authors investigated the prevalence of low bone density and its risk factors in older Korean patients with schizophrenia. Method In cross-sectional study, 327 inpatients w
Autor:
Je-Wook Kang, Sung-Jin Kim, Dong-Wook Jeon, Minkyung Oh, Joo-Cheol Shim, Bo-Geum Kong, Do-Un Jung, Jung-Joon Moon, Young-Soo Seo
Publikováno v:
International journal of psychiatry in clinical practice. 19(4)
Cognitive dysfunction is a core feature of schizophrenia; deficits often manifest prior to diagnosis and persist throughout the course of the illness. This study was performed to assess the difference in cognitive function and daily living skills bet
Autor:
Eun-Chan Kang, Sang Jin Kim, Ji-Seop Lim, Dong-Wook Jeon, Yeon-Sue Kim, Je Wook Kang, Jung-Joon Moon, Bo-Geum Kong, Do Un Jung
Publikováno v:
European Psychiatry. 33:s273-s273
ObjectiveThe aim of this study was to analyze the clinical characteristics of individuals who used alcohol at the time of attempting suicide.MethodsWe divided 143 individuals who attempted suicide by consuming drugs into two groups on the basis of th
Autor:
Dong-Wook Jeon, J.M. An, Do Un Jung, Bo-Geum Kong, Je Wook Kang, Joo-Cheol Shim, H.S. Kim, Jung-Joon Moon
Publikováno v:
European Psychiatry. 33:S101-S101
ObjectivesTo observe the association between adverse effects of long-term use of antipsychotic drugs in female schizophrenic patients and dopamine D2 receptor (DRD2), cytochrome P450 (CYP) 2D6, estrogen receptor-α gene (ESR1).MethodThe subjects were
Autor:
Ji-Heon Lee, Minkyung Oh, Deanna L. Kelly, Deuk-Man Cho, Do-Un Jung, Sae-Woom Lee, Joo-Cheol Shim, Robert P. McMahon, Sang-Duk Kim, Je-Wook Kang, Sung-Soo Jung, Bo-Geum Kong, Young-Soo Seo
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 37(3)
The aim of this study is to examine the effects of treatment with varenicline, a partial agonist at the α4β2 and full agonist at the α7 nicotine acetylcholine receptor, on cognitive impairments in people with schizophrenia. In all, 120 clinically
Autor:
Young Hoon Kim, Bo Geum Kong, Sung Woo Park, Chan Hong Lee, Jeong Ik Kim, Sun Jung Lee, Jung Goo Lee
Publikováno v:
Psychiatry and clinical neurosciences. 63(4)
Aims: Neurodegenerative processes may be involved in the pathogenesis of tardive dyskinesia (TD), and a growing body of evidence suggests that brain-derived neurotrophic factor (BDNF) plays a role in both the antipsychotic effects and the pathogenesi